Literature DB >> 28428268

Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party.

Mohamad Sobh1, Mauricette Michallet2, Valérie Dubois3, Simona Iacobelli4, Linda Koster5, Anja Van Biezen5, Nathalie Fegueux6, Reza Tabrizi7, Jürgen Finke8, Jean El-Cheikh9, Martin Schipperus10, Ellen Meijer11, Peter von dem Borne12, Eefke Petersen13, Nigel Russell14, Eleni Tholouli15, Jakob Passweg16, Frédéric Garban17, Johan Maertens18, Patrice Chevalier19, Natacha Maillard20, Liisa Volin21, Sylvie Francois22, Bruno Lioure23, Yves Beguin24, Eliane Gluckman25, Annalisa Ruggeri26, Laurent Garderet26, Nicolaus Kröger27.   

Abstract

Entities:  

Mesh:

Year:  2017        PMID: 28428268      PMCID: PMC5566053          DOI: 10.3324/haematol.2017.165399

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  11 in total

1.  Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.

Authors:  Sagar Lonial; Meletios Dimopoulos; Antonio Palumbo; Darrell White; Sebastian Grosicki; Ivan Spicka; Adam Walter-Croneck; Philippe Moreau; Maria-Victoria Mateos; Hila Magen; Andrew Belch; Donna Reece; Meral Beksac; Andrew Spencer; Heather Oakervee; Robert Z Orlowski; Masafumi Taniwaki; Christoph Röllig; Hermann Einsele; Ka Lung Wu; Anil Singhal; Jesus San-Miguel; Morio Matsumoto; Jessica Katz; Eric Bleickardt; Valerie Poulart; Kenneth C Anderson; Paul Richardson
Journal:  N Engl J Med       Date:  2015-06-02       Impact factor: 91.245

2.  Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party.

Authors:  M Sobh; M Michallet; G Gahrton; S Iacobelli; A van Biezen; S Schönland; E Petersen; N Schaap; F Bonifazi; L Volin; E Meijer; D Niederwieser; J El Cheikh; R Tabrizi; N Fegeux; J Finke; D Bunjes; J Cornelissen; H Einsele; B Bruno; M Potter; R Fanin; M Mohty; L Garderet; N Kröger
Journal:  Leukemia       Date:  2016-04-27       Impact factor: 11.528

3.  Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Authors:  Meletios A Dimopoulos; Albert Oriol; Hareth Nahi; Jesus San-Miguel; Nizar J Bahlis; Saad Z Usmani; Neil Rabin; Robert Z Orlowski; Mieczyslaw Komarnicki; Kenshi Suzuki; Torben Plesner; Sung-Soo Yoon; Dina Ben Yehuda; Paul G Richardson; Hartmut Goldschmidt; Donna Reece; Steen Lisby; Nushmia Z Khokhar; Lisa O'Rourke; Christopher Chiu; Xiang Qin; Mary Guckert; Tahamtan Ahmadi; Philippe Moreau
Journal:  N Engl J Med       Date:  2016-10-06       Impact factor: 91.245

4.  Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

Authors:  Antonio Palumbo; Asher Chanan-Khan; Katja Weisel; Ajay K Nooka; Tamas Masszi; Meral Beksac; Ivan Spicka; Vania Hungria; Markus Munder; Maria V Mateos; Tomer M Mark; Ming Qi; Jordan Schecter; Himal Amin; Xiang Qin; William Deraedt; Tahamtan Ahmadi; Andrew Spencer; Pieter Sonneveld
Journal:  N Engl J Med       Date:  2016-08-25       Impact factor: 91.245

5.  Cord Blood Transplantation for Multiple Myeloma: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation.

Authors:  Koji Kawamura; Hiroyuki Takamatsu; Takashi Ikeda; Tsunehiko Komatsu; Nobuyuki Aotsuka; Itsuto Amano; Go Yamamoto; Kentaro Watanabe; Yuju Ohno; Kosei Matsue; Yasuji Kouzai; Nobuhiro Tsukada; Ken Ishiyama; Naoyuki Anzai; Koji Kato; Ritsuro Suzuki; Kazutaka Sunami; Yoshinobu Kanda
Journal:  Biol Blood Marrow Transplant       Date:  2015-02-21       Impact factor: 5.742

6.  Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Authors:  A Keith Stewart; S Vincent Rajkumar; Meletios A Dimopoulos; Tamás Masszi; Ivan Špička; Albert Oriol; Roman Hájek; Laura Rosiñol; David S Siegel; Georgi G Mihaylov; Vesselina Goranova-Marinova; Péter Rajnics; Aleksandr Suvorov; Ruben Niesvizky; Andrzej J Jakubowiak; Jesus F San-Miguel; Heinz Ludwig; Michael Wang; Vladimír Maisnar; Jiri Minarik; William I Bensinger; Maria-Victoria Mateos; Dina Ben-Yehuda; Vishal Kukreti; Naseem Zojwalla; Margaret E Tonda; Xinqun Yang; Biao Xing; Philippe Moreau; Antonio Palumbo
Journal:  N Engl J Med       Date:  2014-12-06       Impact factor: 91.245

7.  Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.

Authors:  Nicolaus Kröger; Anita Badbaran; Tatjana Zabelina; Francis Ayuk; Christine Wolschke; Haefaa Alchalby; Evgeny Klyuchnikov; Djordje Atanackovic; Georgia Schilling; Timon Hansen; Sabine Schwarz; Marion Heinzelmann; Silke Zeschke; Ulrike Bacher; Thomas Stübig; Boris Fehse; Axel R Zander
Journal:  Biol Blood Marrow Transplant       Date:  2012-10-16       Impact factor: 5.742

8.  Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting.

Authors:  Laurent Garderet; Gordon Cook; Holger W Auner; Benedetto Bruno; Henk Lokhorst; Jose Antonio Perez-Simon; Firoozeh Sahebi; Christof Scheid; Curly Morris; Anja van Biezen; Mohamad Sobh; Mauricette Michallet; Gösta Gahrton; Stefan Schönland; Nicolaus Kröger
Journal:  Leuk Lymphoma       Date:  2016-09-21

9.  Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

Authors:  Jesús F San-Miguel; Vânia T M Hungria; Sung-Soo Yoon; Meral Beksac; Meletios Athanasios Dimopoulos; Ashraf Elghandour; Wieslaw Wiktor Jedrzejczak; Andreas Günther; Thanyaphong Na Nakorn; Noppadol Siritanaratkul; Paolo Corradini; Suporn Chuncharunee; Je-Jung Lee; Robert L Schlossman; Tatiana Shelekhova; Kwee Yong; Daryl Tan; Tontanai Numbenjapon; Jamie D Cavenagh; Jian Hou; Richard LeBlanc; Hareth Nahi; Lugui Qiu; Hans Salwender; Stefano Pulini; Philippe Moreau; Krzysztof Warzocha; Darrell White; Joan Bladé; WenMing Chen; Javier de la Rubia; Peter Gimsing; Sagar Lonial; Jonathan L Kaufman; Enrique M Ocio; Ljupco Veskovski; Sang Kyun Sohn; Ming-Chung Wang; Jae Hoon Lee; Hermann Einsele; Monika Sopala; Claudia Corrado; Bourras-Rezki Bengoudifa; Florence Binlich; Paul G Richardson
Journal:  Lancet Oncol       Date:  2014-09-18       Impact factor: 41.316

10.  Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT.

Authors:  Annalisa Paviglianiti; Erick Xavier; Annalisa Ruggeri; Patrice Ceballos; Eric Deconinck; Jan J Cornelissen; Stephanie Nguyen-Quoc; Natacha Maillard; Guillermo Sanz; Pierre-Simon Rohrlich; Laurent Garderet; Fernanda Volt; Vanderson Rocha; Nicolaus Kroeger; Eliane Gluckman; Nathalie Fegueux; Mohamad Mohty
Journal:  Haematologica       Date:  2016-05-26       Impact factor: 9.941

View more
  4 in total

1.  Thiotepa-fludarabine-treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial.

Authors:  Jürgen Finke; Claudia Schmoor; Matthias Stelljes; Andreas Burchert; Peter Dreger; Ute Hegenbart; Eva-Maria Wagner-Drouet; Martin Bornhäuser; Kristina Sohlbach; Natalie Schub; Christian Reicherts; Guido Kobbe; Bertram Glass; Hartmut Bertz; Olga Grishina
Journal:  Bone Marrow Transplant       Date:  2022-08-18       Impact factor: 5.174

Review 2.  Allogeneic Stem Cell Transplantation in Multiple Myeloma.

Authors:  Christine Greil; Monika Engelhardt; Jürgen Finke; Ralph Wäsch
Journal:  Cancers (Basel)       Date:  2021-12-23       Impact factor: 6.639

Review 3.  Current Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma.

Authors:  Jean-Sébastien Claveau; Francis K Buadi; Shaji Kumar
Journal:  Oncol Ther       Date:  2022-04-04

Review 4.  Allogeneic Stem Cell Transplantation in Patients with High-Risk Multiple Myeloma: Utopia or Continuous Challenge in Aiming for Cure?

Authors:  Panayotis Kaloyannidis; John Apostolidis
Journal:  Curr Treat Options Oncol       Date:  2021-06-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.